FIVE PRIME THERAPEUTICS, INC.
DelistedCIK 1175505fmd_1XB3R02DMYYTS24P6R7WSG5TKDManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2011 to Dec 31, 2020, 37 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | 31 | 40 | 50 | 15 | 13 |
| Research and development | 34 | 29 | 33 | 43 | 70 | 94 | 151 | 156 | 114 | 65 |
| Total operating expenses | 45 | 38 | 43 | 57 | 93 | 130 | 191 | 196 | 157 | 106 |
| Operating income | 20 | (28) | (29) | (38) | 287 | (99) | (151) | (146) | (142) | (93) |
| Other non-operating income (expense) | (0) | 0 | 0 | (0) | (0) | – | – | 6 | 5 | 2 |
| Income before taxes | – | – | (29) | (37) | 287 | (97) | (149) | (140) | (137) | (91) |
| Income tax expense | – | 0 | 0 | 0 | 38 | (31) | 2 | 0 | 0 | (7) |
| Net income from continuing operations | – | – | (29) | (37) | 250 | (66) | (150) | (140) | (137) | (84) |
| Net income | 1 | (28) | (29) | (37) | 250 | (66) | (150) | (140) | (137) | (84) |
| Net income to common shareholders | 1 | (28) | (29) | – | – | – | – | – | – | – |